ATE504293T1 - Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung - Google Patents

Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung

Info

Publication number
ATE504293T1
ATE504293T1 AT06015782T AT06015782T ATE504293T1 AT E504293 T1 ATE504293 T1 AT E504293T1 AT 06015782 T AT06015782 T AT 06015782T AT 06015782 T AT06015782 T AT 06015782T AT E504293 T1 ATE504293 T1 AT E504293T1
Authority
AT
Austria
Prior art keywords
treatment
bipolar disorder
carbostyril derivatives
subtype agonists
substituted carbostyril
Prior art date
Application number
AT06015782T
Other languages
German (de)
English (en)
Inventor
Yasufumi Uwahodo
Shaun Jordan
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE504293(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE504293T1 publication Critical patent/ATE504293T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06015782T 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung ATE504293T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29

Publications (1)

Publication Number Publication Date
ATE504293T1 true ATE504293T1 (de) 2011-04-15

Family

ID=25087808

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06015782T ATE504293T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung
AT05023971T ATE362763T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT02716434T ATE322894T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT05023971T ATE362763T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT02716434T ATE322894T1 (de) 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Country Status (19)

Country Link
EP (3) EP1712225B1 (https=)
JP (4) JP4178032B2 (https=)
KR (5) KR100713607B1 (https=)
CN (3) CN1239154C (https=)
AR (4) AR032641A1 (https=)
AT (3) ATE504293T1 (https=)
AU (4) AU2002226752C1 (https=)
BR (1) BR0206237A (https=)
CA (2) CA2429496C (https=)
CY (3) CY1105631T1 (https=)
DE (3) DE60220325T2 (https=)
DK (3) DK1712225T3 (https=)
ES (3) ES2261652T3 (https=)
MX (2) MXPA03006603A (https=)
MY (1) MY129355A (https=)
PH (1) PH12014500937A1 (https=)
PT (3) PT1712225E (https=)
TW (2) TWI331919B (https=)
WO (1) WO2002060423A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
KR100842694B1 (ko) * 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
GEP20084567B (en) * 2003-05-23 2008-12-25 Otsuka Pharma Co Ltd Carbostyril derivatives and mood stabilizers for treating mood disorders
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
DE3721799C2 (de) 1986-07-01 1993-12-23 Mitsubishi Electric Corp Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3155276B2 (ja) * 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
DK0904273T3 (da) * 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
CA2264080A1 (en) * 1996-08-27 1998-03-05 Richard Eric Mewshaw 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
CN1289333A (zh) * 1998-02-03 2001-03-28 美国家用产品公司 用作血清素－1a受体激动剂的噁唑衍生物
ZA992670B (en) * 1998-04-13 2000-10-12 American Home Prod 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists.
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EP1397145B1 (en) * 2001-06-19 2006-09-06 Norbert Müller Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
ES2286755T3 (es) 2007-12-01
WO2002060423A2 (en) 2002-08-08
AU2005201772C1 (en) 2010-06-03
DE60220325D1 (de) 2007-07-05
CA2700314C (en) 2012-04-24
DK1355639T3 (da) 2006-08-14
AU2007201701B2 (en) 2010-06-17
PT1712225E (pt) 2011-04-18
CY1111392T1 (el) 2015-08-05
CA2700314A1 (en) 2002-08-08
TW200522960A (en) 2005-07-16
BR0206237A (pt) 2003-12-23
WO2002060423A3 (en) 2003-04-10
CY1108031T1 (el) 2013-09-04
TWI302832B (en) 2008-11-11
MY129355A (en) 2007-03-30
EP1621198A3 (en) 2006-04-12
AU2002226752C1 (en) 2010-02-18
KR100825705B1 (ko) 2008-04-29
ATE322894T1 (de) 2006-04-15
KR20060085260A (ko) 2006-07-26
JP2007297405A (ja) 2007-11-15
CN1813745A (zh) 2006-08-09
KR20030065570A (ko) 2003-08-06
EP1355639A2 (en) 2003-10-29
CY1105631T1 (el) 2010-12-22
PT1621198E (pt) 2007-06-08
DK1712225T3 (da) 2011-06-20
HK1061805A1 (en) 2004-10-08
DE60220325T2 (de) 2008-01-17
EP1621198B1 (en) 2007-05-23
EP1355639B1 (en) 2006-04-12
ES2261652T3 (es) 2006-11-16
EP1621198A2 (en) 2006-02-01
CN1239154C (zh) 2006-02-01
EP1712225B1 (en) 2011-04-06
DE60239711D1 (de) 2011-05-19
AU2009233591A1 (en) 2009-11-19
AU2002226752B2 (en) 2005-03-17
CN1484524A (zh) 2004-03-24
JP4896831B2 (ja) 2012-03-14
KR100653591B1 (ko) 2006-12-05
AR099754A2 (es) 2016-08-17
CA2429496C (en) 2010-10-19
AR032641A1 (es) 2003-11-19
ES2363366T3 (es) 2011-08-02
DE60210581T2 (de) 2007-04-05
AU2005201772A1 (en) 2005-05-19
MX344556B (es) 2016-12-20
CA2429496A1 (en) 2002-08-08
PH12014500937A1 (en) 2015-09-21
KR20050107822A (ko) 2005-11-15
KR20060028485A (ko) 2006-03-29
JP4178032B2 (ja) 2008-11-12
AU2005201772B2 (en) 2007-05-17
KR100763288B1 (ko) 2007-10-04
JP2011225587A (ja) 2011-11-10
KR100713607B1 (ko) 2007-05-02
JP2004517937A (ja) 2004-06-17
KR100601073B1 (ko) 2006-07-19
AR080849A2 (es) 2012-05-09
ATE362763T1 (de) 2007-06-15
EP1712225A1 (en) 2006-10-18
AU2007201701A1 (en) 2007-05-10
JP2011184460A (ja) 2011-09-22
DK1621198T3 (da) 2007-09-24
TWI331919B (en) 2010-10-21
JP5683010B2 (ja) 2015-03-11
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
CN1879624A (zh) 2006-12-20
MXPA03006603A (es) 2004-02-12
KR20070065425A (ko) 2007-06-22
CN100450485C (zh) 2009-01-14
PT1355639E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
ATE504293T1 (de) Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
ATE401076T1 (de) Chinolinderivate als glucokinase liganden
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
ATE304533T1 (de) Tetrahydrochinolinderivate als muscarinische agonisten
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
HRP20090078A2 (en) Novel pyridazine compound and use thereof
DE60212146D1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR0209149A (pt) Ftalazinonas
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
MA28394B1 (fr) Derives d'heteroaryle pour traitement des virus
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1712225

Country of ref document: EP